Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience
Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survival rates of patients with pure seminoma who has b...
Ausführliche Beschreibung
Autor*in: |
Ali GÖKYER [verfasserIn] Ahmet KÜÇÜKARDA [verfasserIn] Osman KÖSTEK [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch ; Türkisch |
Erschienen: |
2019 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Namık Kemal Tıp Dergisi - Galenos Yayincilik, 2022, 7(2019), 2, Seite 128-132 |
---|---|
Übergeordnetes Werk: |
volume:7 ; year:2019 ; number:2 ; pages:128-132 |
Links: |
---|
Katalog-ID: |
DOAJ015657981 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ015657981 | ||
003 | DE-627 | ||
005 | 20230501192543.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2019 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)DOAJ015657981 | ||
035 | |a (DE-599)DOAJf47cdbdc4c8e48b7b841d782ae0402e3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng |a tur | ||
100 | 0 | |a Ali GÖKYER |e verfasserin |4 aut | |
245 | 1 | 0 | |a Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survival rates of patients with pure seminoma who has been followed in our clinic.Materials and Methods:Documents of the pure seminoma patients who has been followed and treated in our clinic between the years of 2008 and 2018 were studied retrospectively. Patient features, tumour features, treatment regimens, prognosis and folow up after treatment were recorded.Results:86 of 125 patients(68,8%) who has been followed in our clinic with the diagnosis of seminoma were between the ages of 20 and 40. At the time of diagnosis,102 patients(81,6%) were at stage 1,14 patients(%11,2) were at stage 2 and 9 patients(7,2%) were at stage 3 disease. Metastases were detected in only 5 patients at the time of diagnosis. While 63 patients were treated with chemotherapy and 39 patients were treated with radiotherapy. Survival rate was 88,9% for 45 patients who filled in 10 years follow up time. 6 patients died because of disease recurrence and irresponsiveness to the therapy. The prominent features in deceased patients were late stage disease and lung parenchymal recurrence.Conclusion:Different treatment modalities for stage 1 disease were similar in aspect of overall survival. Pulmonary parenchyma recurrence and advanced stage disease were associated with mortality. | ||
650 | 4 | |a seminoma | |
650 | 4 | |a carboplatin | |
650 | 4 | |a radiotherapy | |
650 | 4 | |a follow up | |
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
700 | 0 | |a Ahmet KÜÇÜKARDA |e verfasserin |4 aut | |
700 | 0 | |a Osman KÖSTEK |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Namık Kemal Tıp Dergisi |d Galenos Yayincilik, 2022 |g 7(2019), 2, Seite 128-132 |w (DE-627)1830311751 |x 25870262 |7 nnns |
773 | 1 | 8 | |g volume:7 |g year:2019 |g number:2 |g pages:128-132 |
856 | 4 | 0 | |u https://doaj.org/article/f47cdbdc4c8e48b7b841d782ae0402e3 |z kostenfrei |
856 | 4 | 0 | |u http://namikkemalmedj.com/archives/archive-detail/article-preview/clinical-features-and-follow-up-of-pure-seminoma-c/40381 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2587-0262 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 7 |j 2019 |e 2 |h 128-132 |
author_variant |
a g ag a k ak o k ok |
---|---|
matchkey_str |
article:25870262:2019----::lncletrsnflouoprsmnmcssig |
hierarchy_sort_str |
2019 |
publishDate |
2019 |
allfields |
(DE-627)DOAJ015657981 (DE-599)DOAJf47cdbdc4c8e48b7b841d782ae0402e3 DE-627 ger DE-627 rakwb eng tur Ali GÖKYER verfasserin aut Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survival rates of patients with pure seminoma who has been followed in our clinic.Materials and Methods:Documents of the pure seminoma patients who has been followed and treated in our clinic between the years of 2008 and 2018 were studied retrospectively. Patient features, tumour features, treatment regimens, prognosis and folow up after treatment were recorded.Results:86 of 125 patients(68,8%) who has been followed in our clinic with the diagnosis of seminoma were between the ages of 20 and 40. At the time of diagnosis,102 patients(81,6%) were at stage 1,14 patients(%11,2) were at stage 2 and 9 patients(7,2%) were at stage 3 disease. Metastases were detected in only 5 patients at the time of diagnosis. While 63 patients were treated with chemotherapy and 39 patients were treated with radiotherapy. Survival rate was 88,9% for 45 patients who filled in 10 years follow up time. 6 patients died because of disease recurrence and irresponsiveness to the therapy. The prominent features in deceased patients were late stage disease and lung parenchymal recurrence.Conclusion:Different treatment modalities for stage 1 disease were similar in aspect of overall survival. Pulmonary parenchyma recurrence and advanced stage disease were associated with mortality. seminoma carboplatin radiotherapy follow up Medicine R Ahmet KÜÇÜKARDA verfasserin aut Osman KÖSTEK verfasserin aut In Namık Kemal Tıp Dergisi Galenos Yayincilik, 2022 7(2019), 2, Seite 128-132 (DE-627)1830311751 25870262 nnns volume:7 year:2019 number:2 pages:128-132 https://doaj.org/article/f47cdbdc4c8e48b7b841d782ae0402e3 kostenfrei http://namikkemalmedj.com/archives/archive-detail/article-preview/clinical-features-and-follow-up-of-pure-seminoma-c/40381 kostenfrei https://doaj.org/toc/2587-0262 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2019 2 128-132 |
spelling |
(DE-627)DOAJ015657981 (DE-599)DOAJf47cdbdc4c8e48b7b841d782ae0402e3 DE-627 ger DE-627 rakwb eng tur Ali GÖKYER verfasserin aut Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survival rates of patients with pure seminoma who has been followed in our clinic.Materials and Methods:Documents of the pure seminoma patients who has been followed and treated in our clinic between the years of 2008 and 2018 were studied retrospectively. Patient features, tumour features, treatment regimens, prognosis and folow up after treatment were recorded.Results:86 of 125 patients(68,8%) who has been followed in our clinic with the diagnosis of seminoma were between the ages of 20 and 40. At the time of diagnosis,102 patients(81,6%) were at stage 1,14 patients(%11,2) were at stage 2 and 9 patients(7,2%) were at stage 3 disease. Metastases were detected in only 5 patients at the time of diagnosis. While 63 patients were treated with chemotherapy and 39 patients were treated with radiotherapy. Survival rate was 88,9% for 45 patients who filled in 10 years follow up time. 6 patients died because of disease recurrence and irresponsiveness to the therapy. The prominent features in deceased patients were late stage disease and lung parenchymal recurrence.Conclusion:Different treatment modalities for stage 1 disease were similar in aspect of overall survival. Pulmonary parenchyma recurrence and advanced stage disease were associated with mortality. seminoma carboplatin radiotherapy follow up Medicine R Ahmet KÜÇÜKARDA verfasserin aut Osman KÖSTEK verfasserin aut In Namık Kemal Tıp Dergisi Galenos Yayincilik, 2022 7(2019), 2, Seite 128-132 (DE-627)1830311751 25870262 nnns volume:7 year:2019 number:2 pages:128-132 https://doaj.org/article/f47cdbdc4c8e48b7b841d782ae0402e3 kostenfrei http://namikkemalmedj.com/archives/archive-detail/article-preview/clinical-features-and-follow-up-of-pure-seminoma-c/40381 kostenfrei https://doaj.org/toc/2587-0262 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2019 2 128-132 |
allfields_unstemmed |
(DE-627)DOAJ015657981 (DE-599)DOAJf47cdbdc4c8e48b7b841d782ae0402e3 DE-627 ger DE-627 rakwb eng tur Ali GÖKYER verfasserin aut Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survival rates of patients with pure seminoma who has been followed in our clinic.Materials and Methods:Documents of the pure seminoma patients who has been followed and treated in our clinic between the years of 2008 and 2018 were studied retrospectively. Patient features, tumour features, treatment regimens, prognosis and folow up after treatment were recorded.Results:86 of 125 patients(68,8%) who has been followed in our clinic with the diagnosis of seminoma were between the ages of 20 and 40. At the time of diagnosis,102 patients(81,6%) were at stage 1,14 patients(%11,2) were at stage 2 and 9 patients(7,2%) were at stage 3 disease. Metastases were detected in only 5 patients at the time of diagnosis. While 63 patients were treated with chemotherapy and 39 patients were treated with radiotherapy. Survival rate was 88,9% for 45 patients who filled in 10 years follow up time. 6 patients died because of disease recurrence and irresponsiveness to the therapy. The prominent features in deceased patients were late stage disease and lung parenchymal recurrence.Conclusion:Different treatment modalities for stage 1 disease were similar in aspect of overall survival. Pulmonary parenchyma recurrence and advanced stage disease were associated with mortality. seminoma carboplatin radiotherapy follow up Medicine R Ahmet KÜÇÜKARDA verfasserin aut Osman KÖSTEK verfasserin aut In Namık Kemal Tıp Dergisi Galenos Yayincilik, 2022 7(2019), 2, Seite 128-132 (DE-627)1830311751 25870262 nnns volume:7 year:2019 number:2 pages:128-132 https://doaj.org/article/f47cdbdc4c8e48b7b841d782ae0402e3 kostenfrei http://namikkemalmedj.com/archives/archive-detail/article-preview/clinical-features-and-follow-up-of-pure-seminoma-c/40381 kostenfrei https://doaj.org/toc/2587-0262 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2019 2 128-132 |
allfieldsGer |
(DE-627)DOAJ015657981 (DE-599)DOAJf47cdbdc4c8e48b7b841d782ae0402e3 DE-627 ger DE-627 rakwb eng tur Ali GÖKYER verfasserin aut Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survival rates of patients with pure seminoma who has been followed in our clinic.Materials and Methods:Documents of the pure seminoma patients who has been followed and treated in our clinic between the years of 2008 and 2018 were studied retrospectively. Patient features, tumour features, treatment regimens, prognosis and folow up after treatment were recorded.Results:86 of 125 patients(68,8%) who has been followed in our clinic with the diagnosis of seminoma were between the ages of 20 and 40. At the time of diagnosis,102 patients(81,6%) were at stage 1,14 patients(%11,2) were at stage 2 and 9 patients(7,2%) were at stage 3 disease. Metastases were detected in only 5 patients at the time of diagnosis. While 63 patients were treated with chemotherapy and 39 patients were treated with radiotherapy. Survival rate was 88,9% for 45 patients who filled in 10 years follow up time. 6 patients died because of disease recurrence and irresponsiveness to the therapy. The prominent features in deceased patients were late stage disease and lung parenchymal recurrence.Conclusion:Different treatment modalities for stage 1 disease were similar in aspect of overall survival. Pulmonary parenchyma recurrence and advanced stage disease were associated with mortality. seminoma carboplatin radiotherapy follow up Medicine R Ahmet KÜÇÜKARDA verfasserin aut Osman KÖSTEK verfasserin aut In Namık Kemal Tıp Dergisi Galenos Yayincilik, 2022 7(2019), 2, Seite 128-132 (DE-627)1830311751 25870262 nnns volume:7 year:2019 number:2 pages:128-132 https://doaj.org/article/f47cdbdc4c8e48b7b841d782ae0402e3 kostenfrei http://namikkemalmedj.com/archives/archive-detail/article-preview/clinical-features-and-follow-up-of-pure-seminoma-c/40381 kostenfrei https://doaj.org/toc/2587-0262 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2019 2 128-132 |
allfieldsSound |
(DE-627)DOAJ015657981 (DE-599)DOAJf47cdbdc4c8e48b7b841d782ae0402e3 DE-627 ger DE-627 rakwb eng tur Ali GÖKYER verfasserin aut Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survival rates of patients with pure seminoma who has been followed in our clinic.Materials and Methods:Documents of the pure seminoma patients who has been followed and treated in our clinic between the years of 2008 and 2018 were studied retrospectively. Patient features, tumour features, treatment regimens, prognosis and folow up after treatment were recorded.Results:86 of 125 patients(68,8%) who has been followed in our clinic with the diagnosis of seminoma were between the ages of 20 and 40. At the time of diagnosis,102 patients(81,6%) were at stage 1,14 patients(%11,2) were at stage 2 and 9 patients(7,2%) were at stage 3 disease. Metastases were detected in only 5 patients at the time of diagnosis. While 63 patients were treated with chemotherapy and 39 patients were treated with radiotherapy. Survival rate was 88,9% for 45 patients who filled in 10 years follow up time. 6 patients died because of disease recurrence and irresponsiveness to the therapy. The prominent features in deceased patients were late stage disease and lung parenchymal recurrence.Conclusion:Different treatment modalities for stage 1 disease were similar in aspect of overall survival. Pulmonary parenchyma recurrence and advanced stage disease were associated with mortality. seminoma carboplatin radiotherapy follow up Medicine R Ahmet KÜÇÜKARDA verfasserin aut Osman KÖSTEK verfasserin aut In Namık Kemal Tıp Dergisi Galenos Yayincilik, 2022 7(2019), 2, Seite 128-132 (DE-627)1830311751 25870262 nnns volume:7 year:2019 number:2 pages:128-132 https://doaj.org/article/f47cdbdc4c8e48b7b841d782ae0402e3 kostenfrei http://namikkemalmedj.com/archives/archive-detail/article-preview/clinical-features-and-follow-up-of-pure-seminoma-c/40381 kostenfrei https://doaj.org/toc/2587-0262 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2019 2 128-132 |
language |
English Turkish |
source |
In Namık Kemal Tıp Dergisi 7(2019), 2, Seite 128-132 volume:7 year:2019 number:2 pages:128-132 |
sourceStr |
In Namık Kemal Tıp Dergisi 7(2019), 2, Seite 128-132 volume:7 year:2019 number:2 pages:128-132 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
seminoma carboplatin radiotherapy follow up Medicine R |
isfreeaccess_bool |
true |
container_title |
Namık Kemal Tıp Dergisi |
authorswithroles_txt_mv |
Ali GÖKYER @@aut@@ Ahmet KÜÇÜKARDA @@aut@@ Osman KÖSTEK @@aut@@ |
publishDateDaySort_date |
2019-01-01T00:00:00Z |
hierarchy_top_id |
1830311751 |
id |
DOAJ015657981 |
language_de |
englisch türkisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ015657981</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501192543.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ015657981</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf47cdbdc4c8e48b7b841d782ae0402e3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">tur</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ali GÖKYER</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survival rates of patients with pure seminoma who has been followed in our clinic.Materials and Methods:Documents of the pure seminoma patients who has been followed and treated in our clinic between the years of 2008 and 2018 were studied retrospectively. Patient features, tumour features, treatment regimens, prognosis and folow up after treatment were recorded.Results:86 of 125 patients(68,8%) who has been followed in our clinic with the diagnosis of seminoma were between the ages of 20 and 40. At the time of diagnosis,102 patients(81,6%) were at stage 1,14 patients(%11,2) were at stage 2 and 9 patients(7,2%) were at stage 3 disease. Metastases were detected in only 5 patients at the time of diagnosis. While 63 patients were treated with chemotherapy and 39 patients were treated with radiotherapy. Survival rate was 88,9% for 45 patients who filled in 10 years follow up time. 6 patients died because of disease recurrence and irresponsiveness to the therapy. The prominent features in deceased patients were late stage disease and lung parenchymal recurrence.Conclusion:Different treatment modalities for stage 1 disease were similar in aspect of overall survival. Pulmonary parenchyma recurrence and advanced stage disease were associated with mortality.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">seminoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">carboplatin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">radiotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">follow up</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ahmet KÜÇÜKARDA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Osman KÖSTEK</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Namık Kemal Tıp Dergisi</subfield><subfield code="d">Galenos Yayincilik, 2022</subfield><subfield code="g">7(2019), 2, Seite 128-132</subfield><subfield code="w">(DE-627)1830311751</subfield><subfield code="x">25870262</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:128-132</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f47cdbdc4c8e48b7b841d782ae0402e3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://namikkemalmedj.com/archives/archive-detail/article-preview/clinical-features-and-follow-up-of-pure-seminoma-c/40381</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2587-0262</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2019</subfield><subfield code="e">2</subfield><subfield code="h">128-132</subfield></datafield></record></collection>
|
author |
Ali GÖKYER |
spellingShingle |
Ali GÖKYER misc seminoma misc carboplatin misc radiotherapy misc follow up misc Medicine misc R Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience |
authorStr |
Ali GÖKYER |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)1830311751 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut |
collection |
DOAJ |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
25870262 |
topic_title |
Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience seminoma carboplatin radiotherapy follow up |
topic |
misc seminoma misc carboplatin misc radiotherapy misc follow up misc Medicine misc R |
topic_unstemmed |
misc seminoma misc carboplatin misc radiotherapy misc follow up misc Medicine misc R |
topic_browse |
misc seminoma misc carboplatin misc radiotherapy misc follow up misc Medicine misc R |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Namık Kemal Tıp Dergisi |
hierarchy_parent_id |
1830311751 |
hierarchy_top_title |
Namık Kemal Tıp Dergisi |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)1830311751 |
title |
Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience |
ctrlnum |
(DE-627)DOAJ015657981 (DE-599)DOAJf47cdbdc4c8e48b7b841d782ae0402e3 |
title_full |
Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience |
author_sort |
Ali GÖKYER |
journal |
Namık Kemal Tıp Dergisi |
journalStr |
Namık Kemal Tıp Dergisi |
lang_code |
eng tur |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2019 |
contenttype_str_mv |
txt |
container_start_page |
128 |
author_browse |
Ali GÖKYER Ahmet KÜÇÜKARDA Osman KÖSTEK |
container_volume |
7 |
format_se |
Elektronische Aufsätze |
author-letter |
Ali GÖKYER |
author2-role |
verfasserin |
title_sort |
clinical features and follow-up of pure seminoma cases: single center experience |
title_auth |
Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience |
abstract |
Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survival rates of patients with pure seminoma who has been followed in our clinic.Materials and Methods:Documents of the pure seminoma patients who has been followed and treated in our clinic between the years of 2008 and 2018 were studied retrospectively. Patient features, tumour features, treatment regimens, prognosis and folow up after treatment were recorded.Results:86 of 125 patients(68,8%) who has been followed in our clinic with the diagnosis of seminoma were between the ages of 20 and 40. At the time of diagnosis,102 patients(81,6%) were at stage 1,14 patients(%11,2) were at stage 2 and 9 patients(7,2%) were at stage 3 disease. Metastases were detected in only 5 patients at the time of diagnosis. While 63 patients were treated with chemotherapy and 39 patients were treated with radiotherapy. Survival rate was 88,9% for 45 patients who filled in 10 years follow up time. 6 patients died because of disease recurrence and irresponsiveness to the therapy. The prominent features in deceased patients were late stage disease and lung parenchymal recurrence.Conclusion:Different treatment modalities for stage 1 disease were similar in aspect of overall survival. Pulmonary parenchyma recurrence and advanced stage disease were associated with mortality. |
abstractGer |
Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survival rates of patients with pure seminoma who has been followed in our clinic.Materials and Methods:Documents of the pure seminoma patients who has been followed and treated in our clinic between the years of 2008 and 2018 were studied retrospectively. Patient features, tumour features, treatment regimens, prognosis and folow up after treatment were recorded.Results:86 of 125 patients(68,8%) who has been followed in our clinic with the diagnosis of seminoma were between the ages of 20 and 40. At the time of diagnosis,102 patients(81,6%) were at stage 1,14 patients(%11,2) were at stage 2 and 9 patients(7,2%) were at stage 3 disease. Metastases were detected in only 5 patients at the time of diagnosis. While 63 patients were treated with chemotherapy and 39 patients were treated with radiotherapy. Survival rate was 88,9% for 45 patients who filled in 10 years follow up time. 6 patients died because of disease recurrence and irresponsiveness to the therapy. The prominent features in deceased patients were late stage disease and lung parenchymal recurrence.Conclusion:Different treatment modalities for stage 1 disease were similar in aspect of overall survival. Pulmonary parenchyma recurrence and advanced stage disease were associated with mortality. |
abstract_unstemmed |
Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survival rates of patients with pure seminoma who has been followed in our clinic.Materials and Methods:Documents of the pure seminoma patients who has been followed and treated in our clinic between the years of 2008 and 2018 were studied retrospectively. Patient features, tumour features, treatment regimens, prognosis and folow up after treatment were recorded.Results:86 of 125 patients(68,8%) who has been followed in our clinic with the diagnosis of seminoma were between the ages of 20 and 40. At the time of diagnosis,102 patients(81,6%) were at stage 1,14 patients(%11,2) were at stage 2 and 9 patients(7,2%) were at stage 3 disease. Metastases were detected in only 5 patients at the time of diagnosis. While 63 patients were treated with chemotherapy and 39 patients were treated with radiotherapy. Survival rate was 88,9% for 45 patients who filled in 10 years follow up time. 6 patients died because of disease recurrence and irresponsiveness to the therapy. The prominent features in deceased patients were late stage disease and lung parenchymal recurrence.Conclusion:Different treatment modalities for stage 1 disease were similar in aspect of overall survival. Pulmonary parenchyma recurrence and advanced stage disease were associated with mortality. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
2 |
title_short |
Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience |
url |
https://doaj.org/article/f47cdbdc4c8e48b7b841d782ae0402e3 http://namikkemalmedj.com/archives/archive-detail/article-preview/clinical-features-and-follow-up-of-pure-seminoma-c/40381 https://doaj.org/toc/2587-0262 |
remote_bool |
true |
author2 |
Ahmet KÜÇÜKARDA Osman KÖSTEK |
author2Str |
Ahmet KÜÇÜKARDA Osman KÖSTEK |
ppnlink |
1830311751 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
up_date |
2024-07-03T16:15:48.246Z |
_version_ |
1803575202413543424 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ015657981</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501192543.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ015657981</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf47cdbdc4c8e48b7b841d782ae0402e3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">tur</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ali GÖKYER</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical Features and Follow-up of Pure Seminoma Cases: Single Center Experience</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survival rates of patients with pure seminoma who has been followed in our clinic.Materials and Methods:Documents of the pure seminoma patients who has been followed and treated in our clinic between the years of 2008 and 2018 were studied retrospectively. Patient features, tumour features, treatment regimens, prognosis and folow up after treatment were recorded.Results:86 of 125 patients(68,8%) who has been followed in our clinic with the diagnosis of seminoma were between the ages of 20 and 40. At the time of diagnosis,102 patients(81,6%) were at stage 1,14 patients(%11,2) were at stage 2 and 9 patients(7,2%) were at stage 3 disease. Metastases were detected in only 5 patients at the time of diagnosis. While 63 patients were treated with chemotherapy and 39 patients were treated with radiotherapy. Survival rate was 88,9% for 45 patients who filled in 10 years follow up time. 6 patients died because of disease recurrence and irresponsiveness to the therapy. The prominent features in deceased patients were late stage disease and lung parenchymal recurrence.Conclusion:Different treatment modalities for stage 1 disease were similar in aspect of overall survival. Pulmonary parenchyma recurrence and advanced stage disease were associated with mortality.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">seminoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">carboplatin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">radiotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">follow up</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ahmet KÜÇÜKARDA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Osman KÖSTEK</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Namık Kemal Tıp Dergisi</subfield><subfield code="d">Galenos Yayincilik, 2022</subfield><subfield code="g">7(2019), 2, Seite 128-132</subfield><subfield code="w">(DE-627)1830311751</subfield><subfield code="x">25870262</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:128-132</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f47cdbdc4c8e48b7b841d782ae0402e3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://namikkemalmedj.com/archives/archive-detail/article-preview/clinical-features-and-follow-up-of-pure-seminoma-c/40381</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2587-0262</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2019</subfield><subfield code="e">2</subfield><subfield code="h">128-132</subfield></datafield></record></collection>
|
score |
7.399436 |